Articles Referencing ELN

GuruFocus

Seth Klarman Buys Warrants, 2 New Stocks

Seth Klarman , the legendary investor of the Boston-based Baupost Group, bought four new stocks in the first quarter, according to GuruFocus Real Time Picks Data. He is a cautious value... Read >>

Zacks.com

Elan in Royalty Deal with THRX - Analyst Blog

Elan Corporation ( ELN ) recently inked a deal with Theravance Inc. ( THRX ) to purchase a participation interest in potential future royalty payments for a one-time cash payment of... Read >>

Zacks.com

Spectrum Pharma Reports 1Q Loss - Analyst Blog

Spectrum Pharmaceuticals ( SPPI ) reported first quarter of 2013 loss (including stock-based compensation but excluding other special items) of 14 cents per share, narrower than the... Read >>

Zacks.com

Dendreon Narrows 1Q Loss - Analyst Blog

Dendreon Corporation ( DNDN ) reported first-quarter 2013 loss (including stock-based compensation expenses) of 37 cents per share, narrower than the Zacks Consensus Estimate of a loss of... Read >>

Zacks.com

Positive Data on Forest Combo Drug - Analyst Blog

Forest Laboratories, Inc. ( FRX ) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate,... Read >>

Zacks.com

Elan Narrows Y/Y Loss - Analyst Blog

Elan Corporation ( ELN ) reported a loss of 12 cents per share from its continuing operations in the first quarter of 2013, narrower than the year-ago loss of 13 cents per share. Elan's... Read >>

Zacks.com

Elan Turns Down Royalty's Offer - Analyst Blog

Elan Corporation 's ( ELN ) Board of Directors recently rejected Royalty Pharma's offer to acquire all the shares of Elan for $11.25 or less per share. Elan' Board of Directors believed... Read >>

Zacks.com

Elan's Strike Price Stands at $11.25 - Analyst Blog

Elan Corporation ( ELN ) recently announced the final results of its modified Dutch auction tender offer of a maximum aggregate value of $1 billion. The Dutch auction tender offer, which... Read >>

Zacks.com

Elan Responds to Royalty Pharma Offer - Analyst Blog

Elan Corporation 's ( ELN ) Board of Directors recently responded to Echo Pharma Acquisition Limited's ("Royalty Pharma") offer to acquire Elan's shares under Rule 2.5 of the... Read >>

Zacks.com

Elan Gets Takeover Clarity - Analyst Blog

Elan Corporation plc ( ELN ) recently received more visibility regarding its proposed takeover by Royalty Management LLC (Royalty Pharma). The Irish Takeover Panel recently extended the... Read >>

Zacks.com

Elan Sells Off Tysabri Stake - Analyst Blog

Elan Corporation plc ( ELN ) recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ). As a result, Biogen gained full strategic, commercial and... Read >>

Zacks.com

New Data on Biogen/Elan's Tysabri - Analyst Blog

Biogen Idec ( BIIB ) and Elan Corporation plc ( ELN ) recently announced results from several studies of multiple sclerosis drug, Tysabri (natalizumab). Results from the studies showed... Read >>

Zacks.com

Update on Elan's Plans - Analyst Blog

Elan Corporation plc ( ELN ) recently provided an update on its proposed $1billion share repurchase program which is expected to be implemented after the close of the Tysabri (multiple... Read >>

Benzinga

Market Wrap for Monday, March 11: Stocks Continue to Rise to Kick Off Week

After the Dow Jones Industrial Average set four straight record closes last week, stocks are moving higher again on Monday. Overall, traders largely digest last week's better than 2 percent... Read >>

Zacks.com

Elan to Share Tysabri Proceeds - Analyst Blog

Elan Corporation plc 's ( ELN ) Board of Directors recently approved the initiation of a cash dividend policy. The dividend policy will enable the company's shareholders to enjoy long-term... Read >>

Displaying 1-15 of 40
<< first < previous 1 2 3 next > last >>